Evidence map›Paper›PMID 40854885›Full record

ArticleSignal transduction and targeted therapy2025

Bone marrow microenvironment in autoimmune hemolytic anemia: from trephine biopsy to single cell RNA sequencing.

Bruno Fattizzo, Matteo Claudio Da Vià, Francesca Lazzaroni, Alfredo Marchetti, Alessio Marella, Akihiro Maeda, Antonio Giovanni Solimando, Loredana Pettine, Francesco Passamonti, Niccolò Bolli and 1 more

Abstract read
In one paragraph

Article in Signal transduction and targeted therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. CD163Biomarker research · 2026
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bruno Fattizzo *Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. bruno.fattizzo@unimi.it.ORCID 0000-0003-0857-8379
Matteo Claudio Da Vià *Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.ORCID 0000-0002-5396-6584
Francesca LazzaroniFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Alfredo MarchettiFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Alessio MarellaFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Akihiro MaedaFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Antonio Giovanni SolimandoDepartment of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), Unit of Internal Medicine "Guido Baccelli", University of Bari "Aldo Moro" Medical School, Bari, Italy.
Loredana PettineFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Francesco PassamontiFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Niccolò BolliFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Wilma BarcelliniFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The role of bone marrow (BM) compensatory response in autoimmune hemolytic anemias (AIHAs) is emerging and inadequate reticulocytosis has been associated with more severe disease and adverse outcomes. However, few is known about the BM immunologic microenvironment composition in these diseases. Here we investigated BM features in a large cohort of 97 patients with autoimmune hemolytic anemia (AIHA) and observed a high prevalence of hypercellularity, dyserythropoiesis, reticulin fibrosis, and T-cell infiltration (65%, 29%, 76%, and 69% of patients, respectively). These findings were associated with inadequate bone marrow compensation, more severe anemia at onset, and need of multiple treatments. In a subset of warm type AIHA patients we investigated BM microenvironment by single-cell RNA sequencing. We found distinct immune cell profiles across disease stages (diagnosis, remission, relapse). In particular, upregulation of inflammatory response pathways was noted in CD8 + , CD4 + , and monocyte subsets during relapse compared to diagnosis and remission. Moreover, by single-cell TCR sequencing, we found small T cell clones at diagnosis that may either disappeared or expanded at remission. Disappearing clones exhibited a naive CD8+ phenotype and were more likely to respond to glucocorticoid treatment. Expanding clones showed upregulation of cytotoxic T cell markers and may play a role in the transition to a chronic/relapsing phase. Finally, cytokine gene expression differed across disease phases. At relapse, pro-inflammatory cytokines such as TNF-alpha, IL-1, and IL-6 were upregulated in CD4+ and CD8 + T cells, while TGF-beta was downregulated, potentially in an attempt to counteract the transition to chronic phase. This is the largest study evaluating BM histology and clinical characteristics, and the first evaluation of BM microenvironment by single-cell RNA sequencing in AIHA. We showed a complex scenario encompassing T-cell infiltration, clonality, and up/down-regulation of cytokine genes, associated with a more severe and relapsing disease.

Indexed as

Anemia, Hemolytic, AutoimmuneBone MarrowCellular MicroenvironmentAdultAgedBiopsyFemaleHumansMaleMiddle AgedSequence Analysis, RNASingle-Cell Analysis

Identifiers

PMID40854885
PMCPMC12379653

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.